NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Durata Therapeutics Inc. (Nasdaq:DRTX) (“Durata”) in connection with the sale of the Company to Actavis (NYSE: ACT).
Click here to learn about the case: http://docs.wongesq.com/DRTX-Info-Request-Form-431. There is no cost or obligation to you.
Under the terms of the transaction, Durata shareholders will receive $23.00 in cash for each share of Durata common stock they own, as well as contingent value rights entitling the holder to additional cash payments of up to $5.00 per share upon the achievement of particular milestones. The investigation concerns whether the Board of Durata breached their fiduciary duty to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Actavis is underpaying for Durata shares.
If you own common stock in Durata and wish to obtain additional information, please contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/DRTX-Info-Request-Form-431.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.